Clinical trials
Observational Appendiceal Neoplasms trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
17 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2005 | 1 |
| 2014 | 1 |
| 2016 | 1 |
| 2018 | 2 |
| 2019 | 1 |
| 2021 | 3 |
| 2022 | 3 |
| 2023 | 1 |
| 2024 | 2 |
| 2026 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 8 |
| Recruiting | 4 |
| Unknown status | 3 |
| Active, not recruiting | 1 |
| Withdrawn | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | 2 |
| Travera Inc | 2 |
| Andreana Holowatyj, PhD, MSCI | 1 |
| Appendix Cancer Pseudomyxoma Peritonei Research Foundation | 1 |
| City of Hope Medical Center | 1 |
| Edward Hospital | 1 |
| Gangnam Severance Hospital | 1 |
| Holy Name Medical Center, Inc. | 1 |
| M.D. Anderson Cancer Center | 1 |
| Mansoura University | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Appendiceal Neoplasms | 17 |
| Colorectal Neoplasms | 5 |
| Ovarian Neoplasms | 5 |
| Pancreatic Neoplasms | 5 |
| Stomach Neoplasms | 5 |
| Pseudomyxoma Peritonei | 4 |
| Uterine Cervical Neoplasms | 4 |
| Adenocarcinoma, Mucinous | 3 |
| Anus Neoplasms | 3 |
| Breast Neoplasms | 3 |
Trials
Showing 51 to 17 of 17. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.